Dermatology

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Webinars
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at [email protected] Contact no. 011-43720751

Home

Ruchika Sharma

Articles By : Ruchika Sharma

Sun Pharma Seals Rs 97,500 Crore Organon Acquisition Deal

Sun Pharma concludes acquisition of Checkpoint Therapeutics

Written By Ruchika Sharma31 May 2025 12:27 PM IST

Mumbai: Sun Pharmaceutical Industries Limited has announced the successful completion of its acquisition of Checkpoint Therapeutics, Inc., an...

After 40 Years, USFDA Approves Vanda Pharmas Motion Sickness Drug Nereus

Alembic Pharma bags USFDA okay for blood cancer drug Bosutinib

Written By Ruchika Sharma30 May 2025 2:52 PM IST

Vadodara: Alembic Pharmaceuticals Limited has announced that the company has received final approval from the US Food & Drug Administration...

AstraZeneca Gets SEC Nod to Update Lokelma Prescribing Information for Hyperkalemia Treatment

AstraZeneca gets CDSCO nod for new indications of Benralizumab, Osimertinib in India

Written By Ruchika Sharma30 May 2025 1:00 PM IST

Bangalore: AstraZeneca Pharma India Limited has received regulatory approval from the Central Drugs Standard Control Organisation...

$Roche Lunsumio subcutaneous secures European Commission approval for refractory follicular lymphoma$

Bristol Myers Squibb bags European Commission nod for Subcutaneous formulation of Opdivo across multiple solid tumor indications

Written By Ruchika Sharma29 May 2025 10:00 AM IST

Princeton: Bristol Myers Squibb has received approval from the European Commission (EC) for a new Opdivo (nivolumab) formulation...

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok

Articles By : Ruchika Sharma

Sun Pharma concludes acquisition of Checkpoint Therapeutics

Alembic Pharma bags USFDA okay for blood cancer drug Bosutinib

AstraZeneca gets CDSCO nod for new indications of Benralizumab, Osimertinib in India

Marksans Pharma arm adds Metformin Hydrochloride 500mg/ 5 ml Oral Solution to growing list of UK approved medicines

USFDA approves Abbott Tendyne to replace mitral valve without open-heart surgery

AstraZeneca Imfinzi recommended for approval in EU for adults with muscle-invasive bladder cancer

Eli Lilly to acquire SiteOne Therapeutics in USD 1 billion deal

Bayer Sevabertinib gets USFDA Priority Review status for HER2-mutant non-small cell lung cancer

Bristol Myers Squibb bags European Commission nod for Subcutaneous formulation of Opdivo across multiple solid tumor indications

USFDA grants Fast Track Designation to Zydus Usnoflast for amyotrophic lateral sclerosis

WHO unveils new guideline to improve global access to controlled medicines

Lupin to present data from Phase 1a trial evaluating LNP7457 at ASCO annual meeting